Dyne Therapeutics, Inc.
DYN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DYN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DYN
Dyne Therapeutics is a clinical-stage biotechnology company developing oligonucleotide therapies for genetically defined neuromuscular diseases, with lead programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) and a key PDUFA date in January 2027.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 6 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 5 catalysts for Dyne Therapeutics, Inc..
Similar companies
Dyne Therapeutics is a clinical-stage biotechnology company developing oligonucleotide therapies for genetically defined neuromuscular diseases, with lead programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) and a key PDUFA date in January 2027.
- Cash, cash equivalents and marketable securities of $1.1 billion as of December 31, 2025 [sec · filed 2026-04-23].
- Net loss of -$178.6M for the six months ended June 30, 2026 [latest reported financials].
- Accumulated deficit of $1.7 billion as of June 30, 2026 [sec_mda · as of 2026-07-29].
- Lead programs: z-rostudirsen (DMD, exon 51 skipping) and z-basivarsen (DM1) [sec · filed 2026-04-23].
- PDUFA date for z-rostudirsen is January 21, 2027 [upcoming catalysts].
What works
- Cash runway extended into the first quarter of 2028 as of December 31, 2025 [sec · filed 2026-04-23].
- Company raised $140.6M in net proceeds from at-the-market offerings and $594.0M from equity offerings in 2025 [sec · filed 2026-04-23].
- Lead programs are in registrational expansion cohorts with potential for accelerated approval pathways [sec_mda · as of 2025-11-05].
- Proprietary FORCE platform supports pipeline expansion into FSHD, Pompe, and other indications [sec_mda · as of 2026-07-29].
What to weigh
- Accumulated deficit of $1.7 billion as of June 30, 2026, with significant ongoing operating losses [sec_mda · as of 2026-07-29].
- Cash runway estimate assumes positive data and no additional FDA testing; failure could require additional funding [sec_mda · as of 2025-11-05].
- Clinical development is highly uncertain, with risks including trial timing, regulatory paths, and need for further capital [sec_mda · as of 2026-07-29].
- Total debt of $199.3M as of June 30, 2026, adds financial obligations [latest reported financials].
From the filings
Quoted directly from source documents.
Cash runway extended into first quarter of 2028
“on our capital strategy to extend our expected cash runway into the first quarter of 2028”
SEC filings · April 23, 2026
Accumulated deficit of $1.7 billion
“As of June 30, 2026, we had an accumulated deficit of $1.7 billion”
SEC MD&A · July 29, 2026
Cash and securities of $1.1 billion at year-end 2025
“As of December 31, 2025, we had cash, cash equivalents and marketable securities of $1.1 billion”
SEC filings · April 23, 2026
Catalyst timeline
- 2027-01-21 · PDUFA · zeleciment rostudirsen (z-rostudirsen) — FDA decision on marketing approval for z-rostudirsen in DMD amenable to exon 51 skipping.
- 2027-03-31 · Phase2_Topline · z-basivarsen — Phase 2 readout for z-basivarsen in DM1.
- 2027-03-31 · Phase2_Topline · zeleciment basivarsen — Phase 2 readout for zeleciment basivarsen in DM1.
- 2029-01-01 · Phase3_Topline — Phase 3 topline data from a 48-week placebo-controlled study in DMD.
- 2032-10-01 · Phase3_Topline — Phase 3 topline data from a placebo-controlled study in an undisclosed indication.
Risks & what to watch (4)›
Key risks
- Clinical trial uncertainty — Successful development is highly uncertain due to risks in timing, regulatory paths, and funding needs [sec_mda · as of 2026-07-29].
- Cash runway dependency — Runway into Q1 2028 assumes positive data and no additional FDA testing; failure may require more capital [sec_mda · as of 2025-11-05].
- Accumulated deficit — Accumulated deficit of $1.7B as of June 30, 2026, with ongoing losses [sec_mda · as of 2026-07-29].
- Debt obligations — Total debt of $199.3M as of June 30, 2026, adds financial leverage [latest reported financials].
What to watch
- PDUFA decision for z-rostudirsen on January 21, 2027 [upcoming catalysts].
- Phase 2 topline data for z-basivarsen and zeleciment basivarsen expected by March 31, 2027 [upcoming catalysts].
- Phase 3 topline data for the DMD program expected around 2029 [upcoming catalysts].
- Cash burn rate and any additional financing activities [sec_mda · as of 2026-07-29].
Sources: SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Dyne Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dyne Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
20.7 months
D/E 0.42
Lead: Phase 3
2 candidates
5 upcoming, next in ~144d
7 buys · 114 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
225
Total value held
$3.00B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 27,294,752 | $494.9M |
| vanguard capital management llc | 12,810,138 | $232.2M |
| blackrock, inc. | 11,699,870 | $212.1M |
| perceptive advisors llc | 9,337,678 | $169.3M |
| fmr llc | 8,908,980 | $161.5M |
| state street corp | 6,653,746 | $120.6M |
| fcpm iii services b.v. | 4,644,386 | $84.2M |
| tcg crossover management, llc | 4,615,144 | $83.7M |
| vanguard portfolio management llc | 4,162,041 | $75.5M |
| vestal point capital, lp | 4,000,000 | $72.5M |
Showing top 10 of 225 institutional holders of Dyne Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 13.6%
- Days to cover
- 7.7
- Shares short
- 20,465,591
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DYN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Dyne Therapeutics, Inc.?
Dyne Therapeutics is a clinical-stage biotechnology company developing oligonucleotide therapies for genetically defined neuromuscular diseases, with lead programs in Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) and a key PDUFA date in January 2027.
What is Dyne Therapeutics, Inc.'s lead drug candidate?
Dyne Therapeutics, Inc.'s most advanced tracked candidate is DYNE-101 (Phase 3) for Myotonic Dystrophy Type 1 (DM1).
What is Dyne Therapeutics, Inc.'s next catalyst?
Dyne Therapeutics, Inc.'s next tracked catalyst is a PDUFA event — "PDUFA Date: zeleciment rostudirsen (z-rostudirsen" — expected January 21, 2027.
Who is the CEO of Dyne Therapeutics, Inc.?
Mr. John G. Cox M.B.A. is the chief executive officer of Dyne Therapeutics, Inc. (DYN).
Where is Dyne Therapeutics, Inc. headquartered?
Dyne Therapeutics, Inc. (DYN) is headquartered in Waltham, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.